Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ayisha Sharma

Reporter

London, UK

Ayisha joined Scrip in 2021 after working as an investigative reporter at GlobalData's pharmaceutical news platform, BioPharm Insight, where she covered the beats of hematology, oncology and rare diseases. She holds an MA in Philosophy from University College London and an NCTJ diploma in multimedia journalism. Ayisha is interested in psychiatric disorders and drug development focused on the microbiome.

Latest From Ayisha Sharma

Certa Plans Pivotal Scleroderma Trial As GPCR Antagonist Hits Phase II Bullseye

Certa’s lead candidate has shown promise in a mid-stage trial for the rare but debilitating skin disorder, triggering pivotal development plans to address the high unmet need.

Clinical Trials Rare Diseases

Idorsia’s Clazosentan Fails Yet Another Pivotal Brain Injury Trial As Cash Runway Dwindles

Funding pressures grow as the Swiss firm’s endothelin A receptor antagonist clazosentan once again misses the mark in a Phase III brain injury trial aimed at breaking into the Western market, despite prior success in similar Japanese trials.

Clinical Trials Neurology

Sanofi Reports Uninspiring Q4 Sales Amid Skepticism On Dupixent’s COPD Potential

The French firm’s Q4 sales missed consensus due to a slow-down in its vaccine franchise, while analyst concern regarding a pivotal readout for blockbuster product Dupixent in COPD increased.

Sales & Earnings Companies

Executives On The Move: Grey Wolf Therapeutics, Fresh Tracks Therapeutics And More

Recent executive moves in the industry include C-suite changes at Fresh Tracks Therapeutics and Protara Therapeutics. Meanwhile, new directors were appointed at Grey Wolf Therapeutics and BioSenic.

Executive Changes Leadership

Label Woes For GSK’s Jesduvroq Dampen US Anemic Kidney Disease Approval

The UK major’s Jesduvroq has become the first drug of its class to win US approval for anemic kidney disease but significant label restrictions have left some analysts lukewarm on its sales potential.

Approvals Commercial

Novo’s Wegovy Back On Track In Q4 But Broader Supply Issues Remain

Now that US supply of the Danish firm’s blockbuster obesity product is back in full swing, Novo is focusing on diversifying its pipeline to reduce dependence on its GLP-1 franchise.

Sales & Earnings Commercial
See All
UsernamePublicRestriction

Register